Cemiplimab (Regeneron/Sanofi) is a programmed death-1 (PD-1)-targeted monoclonal antibody. The interaction between PD-1 and its ligand PD-L1 on a T cell reduces T-cell function signals, resulting in tumor cell survival and proliferation due to immune system suppression. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses.
4 Drug Overview
5 Product Profiles
5 cemiplimab : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 45: Datamonitor Healthcare’s drug assessment summary for Tagrisso in non-small cell lung cancer
13 Figure 32: Datamonitor Healthcare’s drug assessment summary for Imfinzi in non-small cell lung cancer
LIST OF TABLES
6 Table 1: Cemiplimab drug profile
7 Table 2: Cemiplimab Phase III trials in non-small cell lung cancer
8 Table 3: Cemiplimab early-phase data in non-small cell lung cancer
14 Table 4: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
16 Table 5: Cemiplimab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
10 Table 46: Gilotrif patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.